<DOC>
	<DOC>NCT01670357</DOC>
	<brief_summary>This study is to determine the efficacy and safety of 3% or 5% DA-6034 eye drops compared with placebo in dry eye syndrome.</brief_summary>
	<brief_title>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</brief_title>
	<detailed_description>Eligible subjects are randomly assigned to receive 3% DA-6034, 5% DA-6034 or Placebo. This study is conducted for 6 weeks(Run-in Period 2 weeks + Treatment Period 4 weeks).</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1. Age≥20 2. Dry eye symptoms(irritation, foreign body sensation, burning, mucus discharge, blurring, itching, photophobia, tird or heavy feeling, pain) for more than 6 months 3. Fluorescein corneal staining score ≥ 4 and Schirmer test I ≤ 7mm in same eye 4. Corrected vision ≥ 0.2 in both eye 5. Have given a written, informed consent 1. Ocular disorder that may confound interpretation of study results 2. Current treatment for glaucoma or IOP over 25mmHg 3. Ocular surgery history within 1 year 4. Other malignancy history or uncontrolled severe disease within 5 years 5. Use of systemic immunosuppressive therapies within 3 months 6. Use of opthalmic cyclosporin, opthalmic steroid within 4 weeks 7. Received any other investigational drugs within 4 weeks 8. Subjects who are willing to wear contact lenses during study participation 9. Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
</DOC>